How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Buy
53
CTMX Quote, Financials, Valuation and Earnings
Last price:
$5.70
Seasonality move
:
-6.55%
Day range:
$5.38 - $5.88
52-week range:
$0.40 - $6.15
Dividend yield:
0%
P/E ratio:
13.61x
P/S ratio:
5.78x
P/B ratio:
8.98x
Volume:
2.1M
Avg. volume:
3.5M
1-year change:
550.29%
Market cap:
$964.1M
Revenue:
$138.1M
EPS (TTM):
$0.42
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CTMX
CytomX Therapeutics, Inc.
|
$7.3M | -$0.09 | -86.91% | -23% | $8.50 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
RGNX
REGENXBIO, Inc.
|
$59.3M | -$0.78 | -23.59% | -24.34% | $31.00 |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.37 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CTMX
CytomX Therapeutics, Inc.
|
$5.69 | $8.50 | $964.1M | 13.61x | $0.00 | 0% | 5.78x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$1.86 | $0.85 | $234.7M | 3.12x | $0.80 | 0% | 3.61x |
|
OGEN
Oragenics, Inc.
|
$0.84 | $2.00 | $691.9K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
RGNX
REGENXBIO, Inc.
|
$11.16 | $31.00 | $565M | -- | $0.00 | 0% | 3.53x |
|
TOVX
Theriva Biologics, Inc.
|
$0.18 | $7.00 | $6.1M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CTMX
CytomX Therapeutics, Inc.
|
4.95% | 12.094 | 1.06% | 3.54x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | -3.190 | 8.08% | 1.85x |
|
OGEN
Oragenics, Inc.
|
3.86% | 0.905 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
RGNX
REGENXBIO, Inc.
|
62.42% | -0.953 | 54.89% | 2.40x |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -2.522 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CTMX
CytomX Therapeutics, Inc.
|
$5.8M | -$15.9M | 52.07% | 61.33% | -266.11% | -$15.4M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
RGNX
REGENXBIO, Inc.
|
$20.1M | -$52.4M | -40.97% | -73.5% | -176.27% | -$56.5M |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
CytomX Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns CTMX or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -238.62% compared to CytomX Therapeutics, Inc.'s net margin of -255.85%. CytomX Therapeutics, Inc.'s return on equity of 61.33% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital CTMXCytomX Therapeutics, Inc.97.75% -$0.09 $113M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About CTMX or NBY?
CytomX Therapeutics, Inc. has a consensus price target of $8.50, signalling upside risk potential of 49.39%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -54.3%. Given that CytomX Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe CytomX Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CTMXCytomX Therapeutics, Inc.5 2 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is CTMX or NBY More Risky?
CytomX Therapeutics, Inc. has a beta of 2.424, which suggesting that the stock is 142.412% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.
-
Which is a Better Dividend Stock CTMX or NBY?
CytomX Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. CytomX Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CTMX or NBY?
CytomX Therapeutics, Inc. quarterly revenues are $6M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. CytomX Therapeutics, Inc.'s net income of -$14.2M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, CytomX Therapeutics, Inc.'s price-to-earnings ratio is 13.61x while NovaBay Pharmaceuticals, Inc.'s PE ratio is 3.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytomX Therapeutics, Inc. is 5.78x versus 3.61x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CTMXCytomX Therapeutics, Inc.5.78x 13.61x $6M -$14.2M NBYNovaBay Pharmaceuticals, Inc.3.61x 3.12x $521K -$1.3M
-
Which has Higher Returns CTMX or OGEN?
Oragenics, Inc. has a net margin of -238.62% compared to CytomX Therapeutics, Inc.'s net margin of --. CytomX Therapeutics, Inc.'s return on equity of 61.33% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital CTMXCytomX Therapeutics, Inc.97.75% -$0.09 $113M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About CTMX or OGEN?
CytomX Therapeutics, Inc. has a consensus price target of $8.50, signalling upside risk potential of 49.39%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 137.87%. Given that Oragenics, Inc. has higher upside potential than CytomX Therapeutics, Inc., analysts believe Oragenics, Inc. is more attractive than CytomX Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CTMXCytomX Therapeutics, Inc.5 2 0 OGENOragenics, Inc.1 0 0 -
Is CTMX or OGEN More Risky?
CytomX Therapeutics, Inc. has a beta of 2.424, which suggesting that the stock is 142.412% more volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.903, suggesting its less volatile than the S&P 500 by 9.685%.
-
Which is a Better Dividend Stock CTMX or OGEN?
CytomX Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytomX Therapeutics, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CTMX or OGEN?
CytomX Therapeutics, Inc. quarterly revenues are $6M, which are larger than Oragenics, Inc. quarterly revenues of --. CytomX Therapeutics, Inc.'s net income of -$14.2M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, CytomX Therapeutics, Inc.'s price-to-earnings ratio is 13.61x while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytomX Therapeutics, Inc. is 5.78x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CTMXCytomX Therapeutics, Inc.5.78x 13.61x $6M -$14.2M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns CTMX or PTN?
Palatin Technologies has a net margin of -238.62% compared to CytomX Therapeutics, Inc.'s net margin of --. CytomX Therapeutics, Inc.'s return on equity of 61.33% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CTMXCytomX Therapeutics, Inc.97.75% -$0.09 $113M PTNPalatin Technologies-- -- -- -
What do Analysts Say About CTMX or PTN?
CytomX Therapeutics, Inc. has a consensus price target of $8.50, signalling upside risk potential of 49.39%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than CytomX Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than CytomX Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CTMXCytomX Therapeutics, Inc.5 2 0 PTNPalatin Technologies0 0 0 -
Is CTMX or PTN More Risky?
CytomX Therapeutics, Inc. has a beta of 2.424, which suggesting that the stock is 142.412% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock CTMX or PTN?
CytomX Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytomX Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CTMX or PTN?
CytomX Therapeutics, Inc. quarterly revenues are $6M, which are larger than Palatin Technologies quarterly revenues of --. CytomX Therapeutics, Inc.'s net income of -$14.2M is higher than Palatin Technologies's net income of --. Notably, CytomX Therapeutics, Inc.'s price-to-earnings ratio is 13.61x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytomX Therapeutics, Inc. is 5.78x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CTMXCytomX Therapeutics, Inc.5.78x 13.61x $6M -$14.2M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns CTMX or RGNX?
REGENXBIO, Inc. has a net margin of -238.62% compared to CytomX Therapeutics, Inc.'s net margin of -208.32%. CytomX Therapeutics, Inc.'s return on equity of 61.33% beat REGENXBIO, Inc.'s return on equity of -73.5%.
Company Gross Margin Earnings Per Share Invested Capital CTMXCytomX Therapeutics, Inc.97.75% -$0.09 $113M RGNXREGENXBIO, Inc.67.68% -$1.20 $429.6M -
What do Analysts Say About CTMX or RGNX?
CytomX Therapeutics, Inc. has a consensus price target of $8.50, signalling upside risk potential of 49.39%. On the other hand REGENXBIO, Inc. has an analysts' consensus of $31.00 which suggests that it could grow by 177.78%. Given that REGENXBIO, Inc. has higher upside potential than CytomX Therapeutics, Inc., analysts believe REGENXBIO, Inc. is more attractive than CytomX Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CTMXCytomX Therapeutics, Inc.5 2 0 RGNXREGENXBIO, Inc.6 1 0 -
Is CTMX or RGNX More Risky?
CytomX Therapeutics, Inc. has a beta of 2.424, which suggesting that the stock is 142.412% more volatile than S&P 500. In comparison REGENXBIO, Inc. has a beta of 1.068, suggesting its more volatile than the S&P 500 by 6.832%.
-
Which is a Better Dividend Stock CTMX or RGNX?
CytomX Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. REGENXBIO, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytomX Therapeutics, Inc. pays -- of its earnings as a dividend. REGENXBIO, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CTMX or RGNX?
CytomX Therapeutics, Inc. quarterly revenues are $6M, which are smaller than REGENXBIO, Inc. quarterly revenues of $29.7M. CytomX Therapeutics, Inc.'s net income of -$14.2M is higher than REGENXBIO, Inc.'s net income of -$61.9M. Notably, CytomX Therapeutics, Inc.'s price-to-earnings ratio is 13.61x while REGENXBIO, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytomX Therapeutics, Inc. is 5.78x versus 3.53x for REGENXBIO, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CTMXCytomX Therapeutics, Inc.5.78x 13.61x $6M -$14.2M RGNXREGENXBIO, Inc.3.53x -- $29.7M -$61.9M
-
Which has Higher Returns CTMX or TOVX?
Theriva Biologics, Inc. has a net margin of -238.62% compared to CytomX Therapeutics, Inc.'s net margin of --. CytomX Therapeutics, Inc.'s return on equity of 61.33% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital CTMXCytomX Therapeutics, Inc.97.75% -$0.09 $113M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About CTMX or TOVX?
CytomX Therapeutics, Inc. has a consensus price target of $8.50, signalling upside risk potential of 49.39%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3788.89%. Given that Theriva Biologics, Inc. has higher upside potential than CytomX Therapeutics, Inc., analysts believe Theriva Biologics, Inc. is more attractive than CytomX Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CTMXCytomX Therapeutics, Inc.5 2 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is CTMX or TOVX More Risky?
CytomX Therapeutics, Inc. has a beta of 2.424, which suggesting that the stock is 142.412% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.729%.
-
Which is a Better Dividend Stock CTMX or TOVX?
CytomX Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytomX Therapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CTMX or TOVX?
CytomX Therapeutics, Inc. quarterly revenues are $6M, which are larger than Theriva Biologics, Inc. quarterly revenues of --. CytomX Therapeutics, Inc.'s net income of -$14.2M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, CytomX Therapeutics, Inc.'s price-to-earnings ratio is 13.61x while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytomX Therapeutics, Inc. is 5.78x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CTMXCytomX Therapeutics, Inc.5.78x 13.61x $6M -$14.2M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
50
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Sell
40
GDXU alert for Jan 31
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 38.85% over the past day.
Sell
34
PFSI alert for Jan 31
PennyMac Financial Services, Inc. [PFSI] is down 33.21% over the past day.
Sell
40
SHNY alert for Jan 31
MicroSectors Gold 3X Leveraged ETN [SHNY] is down 31.56% over the past day.
